Lipigo A 150 mg

Lipigo A 150 mg contains Fenofibrate 150 mg (as Fenofibrate) tablet/capsule. Prescription required.

Treatment of high cholesterol and high triglycerides (dyslipidaemia, hypertriglyceridaemia); used to reduce risk of pancreatitis in severe hypertriglyceridaemia; adjunct to diet and lifestyle changes

Fenofibrate activates PPAR-α, increasing lipolysis and clearance of triglyceride-rich lipoproteins. It lowers triglycerides and VLDL, can increase HDL, and improves overall lipid profile.

Oral use. Take exactly as prescribed, usually once daily; swallow whole with water. Often taken with food (follow brand/doctor advice). Continue diet, exercise and weight control while on therapy.

Stomach pain, nausea, diarrhoea, headache, dizziness, elevated liver enzymes, muscle pain/weakness, rash

Not for use in severe kidney disease, active liver disease, gallbladder disease, or known hypersensitivity. Risk of myopathy/rhabdomyolysis increases with statins, in elderly, diabetes, hypothyroidism, or renal impairment—report unexplained muscle pain, tenderness or weakness. Monitor liver function and kidney function periodically. May increase risk of gallstones; stop if pancreatitis is suspected. Dose adjustment/avoid in renal impairment.

Statins (increased myopathy risk), Warfarin/other anticoagulants (increased bleeding—monitor INR), Cyclosporine/tacrolimus (renal risk), Bile acid sequestrants like cholestyramine/colestipol (reduced absorption—separate dosing), Colchicine (myopathy risk)

Store below 25°C in a dry place, protected from light and moisture. Keep out of reach of children.

Fenoglide 160 Tablet, Lipicard 160 Tablet, Feno 160 Tablet, Fenat 160 Tablet, Triglyde 160 Tablet